SiBone (NASDAQ:SIBN) SVP Sells $52,369.14 in Stock

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 3,134 shares of the stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $16.71, for a total transaction of $52,369.14. Following the completion of the sale, the senior vice president directly owned 277,375 shares in the company, valued at approximately $4,634,936.25. The trade was a 1.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

SiBone Trading Down 2.4%

Shares of SiBone stock opened at $16.89 on Thursday. SiBone has a 1 year low of $11.48 and a 1 year high of $21.89. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.99 and a quick ratio of 8.34. The business has a 50 day moving average price of $14.94 and a 200 day moving average price of $15.46. The company has a market capitalization of $749.07 million, a P/E ratio of -43.31 and a beta of 0.67.

SiBone (NASDAQ:SIBN) last announced its earnings results on Monday, May 11th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.07. SiBone had a negative return on equity of 9.56% and a negative net margin of 8.10%.The firm had revenue of $52.59 million for the quarter, compared to analysts’ expectations of $51.16 million. Sell-side analysts anticipate that SiBone will post -0.44 EPS for the current fiscal year.

Hedge Funds Weigh In On SiBone

Several institutional investors and hedge funds have recently bought and sold shares of the stock. First Light Asset Management LLC raised its stake in SiBone by 6.4% during the first quarter. First Light Asset Management LLC now owns 5,353,190 shares of the company’s stock worth $67,611,000 after purchasing an additional 320,286 shares during the period. Vanguard Group Inc. raised its holdings in shares of SiBone by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 2,501,555 shares of the company’s stock worth $49,331,000 after purchasing an additional 11,566 shares during the period. Granahan Investment Management LLC raised its holdings in shares of SiBone by 97.6% in the 1st quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock worth $21,965,000 after purchasing an additional 858,942 shares during the period. Nuveen LLC lifted its stake in shares of SiBone by 5.1% in the 4th quarter. Nuveen LLC now owns 1,421,946 shares of the company’s stock valued at $28,041,000 after purchasing an additional 69,229 shares in the last quarter. Finally, Impax Asset Management Group plc lifted its stake in shares of SiBone by 17.1% in the 4th quarter. Impax Asset Management Group plc now owns 1,200,010 shares of the company’s stock valued at $23,664,000 after purchasing an additional 175,000 shares in the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

Analyst Upgrades and Downgrades

SIBN has been the subject of several analyst reports. Truist Financial reissued a “buy” rating and issued a $18.00 target price (down from $20.00) on shares of SiBone in a research note on Tuesday, May 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of SiBone in a report on Thursday, July 2nd. Wall Street Zen lowered shares of SiBone from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. Finally, TD Cowen reduced their price objective on shares of SiBone from $22.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, May 12th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.00.

About SiBone

Si-BONE, Inc is a commercial?stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA?cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.